

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



贝黎诗  
PALAISPA

CellCare  
| 秀 | 可 | 儿 | 医 | 美 |

NEOLOGY  
研源医疗

**Beauty Farm Medical and Health Industry Inc.**  
**美麗田園醫療健康產業有限公司\***  
(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 2373)

**VOLUNTARY ANNOUNCEMENT**  
**PROPOSED ON-MARKET SHARE REPURCHASE**  
**UNDER THE REPURCHASE MANDATE**

This announcement is made by Beauty Farm Medical and Health Industry Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company announces that the board (the “**Board**”) of directors (the “**Directors**”) of the Company intends to exercise its power under the general mandate to repurchase shares (the “**Shares**”) of the Company (the “**Repurchase Mandate**”) granted by resolution of the shareholders (the “**Shareholders**”) passed in the annual general meeting of the Company held on June 19, 2023 (the “**AGM**”). Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 23,666,106 Shares, being 10% of the number of Shares in issue as at the date of the AGM.

The Company is pleased to announce that, subject to market conditions, it shall, from time to time, conduct on-market repurchase of Shares during the period from the date of this announcement to the expiration or termination Repurchase Mandate. The Company proposes to use up to HK\$60 million for the repurchase of no more than 2.37 million Shares, representing approximately 1% of the issued Shares of the Company. The Board believes that the current financial resources of the Company would enable it to conduct the aforesaid repurchase of Shares while maintaining a solid financial position. Under the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), the actual repurchase price of each Share shall be no more than 5% higher than the average closing market price for the Shares over the five trading days immediately preceding each repurchase.

\* For identification purposes only

The Board considers that the current trading price of the Shares does not reflect their intrinsic value and the actual business prospects of the Company. The Board believes that the proposed share repurchase and subsequent cancellation of the repurchased Shares can enhance the value of the Shares, thereby improving the return to Shareholders. The Board believes that the proposed share repurchase is in the interests of the Company and its Shareholders as a whole.

The proposed share repurchase will be subject to compliance with the Repurchase Mandate, applicable provisions of the Company's memorandum and articles of association, the Listing Rules, The Codes on Takeovers and Mergers and Share Buy-backs (the "Takeovers Code") and other applicable Hong Kong and Cayman Islands laws and regulations. Any Shares repurchased pursuant to the Repurchase Mandate will be cancelled in due course. The Directors have no intention to exercise the Repurchase Mandate to the extent that would result in the number of Shares in the hands of the public falling below the prescribed minimum percentage as required by the Stock Exchange or give rise to an obligation to make a general offer to the Shareholders under Rules 26 and 32 of the Takeovers Code.

**Shareholders and potential investors of the Company are advised that the repurchase of Shares is subject to the sole discretion of the Directors based on the market conditions and that no assurance can be given as to the timing, quantity or price of any repurchase. As such, Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Beauty Farm Medical and Health Industry Inc.**  
**Li Yang**  
*Chairman and executive Director*

Hong Kong, June 28, 2023

*As at the date of this announcement, the Board comprises Mr. Li Yang as Chairman and executive Director, Mr. Lian Songyong as executive Director, Mr. Zhai Feng, Mr. Geng Jiaqi and Ms. Li Fangyu as non-executive Directors and Mr. Fan Mingchao, Mr. Liu Teng and Mr. Jiang Hua as independent non-executive Directors.*